Value-based healthcare is predicated on collaboration. Sharing of data, methods, pathways and perspectives among different stakeholders is paramount if the transition to value-based care is to be fully realized. Instead of relying solely on legacy methods to measure value, IVI's Open-Source Value Platform (OSVP) uses a transparent and open-source process to develop methods and tools [...]
IVI's Director of Scientific Communications, Mark Linthicum, sits down with the Journal of Clinical Pathways for a webinar discussion about IVI's open-source model for assessing value in non-small cell lung cancer therapies. If you want to learn more about IVI's open-source approach to value assessment, this webinar is a great place to start. Click here to [...]
IVI will host two upcoming webinars focused on its new disease-specific, open-source value model to assess EGFR+ non-small cell lung cancer (NSCLC) therapy sequences. These webinars are free and open to the public. We hope you will join us to learn more about IVI's Open-Source Value Project (OSVP) and the new IVI-NSCLC model. Detailed information and [...]
In an article published on AJMC.com, IVI'sJennifer Bright discusses how IVI makes incorporating patients' perspectives a priority in developing open-source, transparent value models. Read the full article here.
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]
IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression [...]
